Rahimi Roja, Nikfar Shekoufeh, Abdollahi Mohammad
Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Med Sci Monit. 2007 Jul;13(7):PI13-8.
TNF-alpha has an important role in the pathogenesis of ulcerative colitis (UC). It therefore seems that infliximab, the antibody against TNF-alpha, is beneficial in the treatment of UC. The aim was to determine whether infliximab induces clinical response and remission in patients with UC using the meta-analysis technique.
MATERIAL/METHODS: The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab on UC. Data from 1966 to 2006 were collected. The keywords used to search were "ulcerative colitis" with "infliximab", "anti tumor necrosis factor", or "anti tumor necrosis factors". The reference lists from the retrieved articles were also reviewed for additional applicable studies.
The summary odds ratio (OR) for clinical remission in four studies was 3.24 with a 95%CI of 1.6-6.57 and a significant OR. The summary OR for clinical response in three studies was 3.93 with a 95%CI of 2.84-5.45 and a significant OR.
Infliximab is effective in inducing response and remission in patients with ulcerative colitis when administered in combination with corticosteroids.
肿瘤坏死因子-α（TNF-α）在溃疡性结肠炎（UC）的发病机制中起重要作用。因此，抗TNF-α抗体英夫利昔单抗似乎对UC治疗有益。本研究旨在采用荟萃分析技术确定英夫利昔单抗是否能诱导UC患者产生临床反应并实现缓解。
材料/方法：检索了Pubmed和Embase数据库中关于英夫利昔单抗治疗UC疗效的研究。收集了1966年至2006年的数据。用于检索的关键词为“溃疡性结肠炎”与“英夫利昔单抗”、“抗肿瘤坏死因子”或“抗肿瘤坏死因子”。还对检索到的文章的参考文献列表进行了审查，以寻找其他适用的研究。
四项研究中临床缓解的汇总比值比（OR）为3.24，95%置信区间为1.6 - 6.57，且OR具有显著性。三项研究中临床反应的汇总OR为3.93，95%置信区间为2.84 - 5.45，且OR具有显著性。
英夫利昔单抗与皮质类固醇联合使用时，对诱导溃疡性结肠炎患者产生反应和缓解有效。
